公开(公告)号：US20100035971A1

公开(公告)日：2010-02-11

申请号：US12086712

申请日：2006-12-21

申请人： Annamari Ranki ,  Sonja Hahtola ,  Leena Karenko ,  Soile Tuomela ,  Riitta Lahesmaa ,  Kai J.E. Krohn

发明人： Annamari Ranki ,  Sonja Hahtola ,  Leena Karenko ,  Soile Tuomela ,  Riitta Lahesmaa ,  Kai J.E. Krohn

IPC分类号： A61K31/7088 ,  C12Q1/68

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

摘要： The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.

摘要翻译： 本发明涉及遗传学和肿瘤学领域，并提供了检测皮肤T细胞淋巴瘤（CTCL）或对CTCL敏感性的方法。 具体地说，本发明涉及一种诊断和追踪CTCL或CTCL亚型的新方法，该方法包括测定一种或多种基因，基因片段或基因产物的表达。 本发明还涉及检测对CTCL治疗的反应的新方法，所述方法包括测定生物样品中一种或多种基因或基因片段或基因产物的表达。 本发明还涉及一种开发或改进CTCL治疗或开发抗CTCL药物的新方法，该方法包括影响一种或几种基因或基因产物的筛选剂。 本发明还涉及一种治疗CTCL患者的新方法，该方法包括影响一种或几种基因或基因产物。 本发明还涉及一种新的测试试剂盒，该试剂盒包含检测一种或多种基因，基因片段或基因产物的必要手段。 本发明还涉及一种或多种基因，基因片段或基因产物用于测定，诊断或追踪CTCL或CTCL亚型以及检测对CTCL治疗的应答​​的用途。 本发明还涉及一种或多种靶分子用于CTCL治疗或制备用于治疗CTCL的药物的用途。

公开(公告)号：US08143029B2

公开(公告)日：2012-03-27

申请号：US12086712

申请日：2006-12-21

申请人： Annamari Ranki ,  Sonja Hahtola ,  Leena Karenko ,  Soile Tuomela ,  Riitta Lahesmaa ,  Kai J. E Krohn

发明人： Annamari Ranki ,  Sonja Hahtola ,  Leena Karenko ,  Soile Tuomela ,  Riitta Lahesmaa ,  Kai J. E Krohn

IPC分类号： C12P19/34 ,  C12Q1/68 ,  C12M1/34

CPC分类号： C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/158

摘要： The present invention relates to the fields of genetics and oncology and provides methods for detecting cutaneous T-cell lymphomas (CTCL) or susceptibility to CTCL. Specifically, the present invention relates to a novel method for the diagnosis and follow-up of CTCL or CTCL subtype, the method comprising determination of expression of one or more genes, gene fragments or gene products. The present invention further relates to a novel method of detecting the response to CTCL therapy, the method comprising determining expression of one or more genes or gene fragments or gene products in a biological sample. The present invention further relates to a novel method of developing or improving CTCL therapy or developing anti-CTCL medicament, the method comprising screening agents affecting one or several of the genes or gene products. The present invention further relates to a novel method of treating CTCL patients, the method comprising affecting one or several of the genes or gene products. The present invention further relates to a novel test kit, the kit comprising the necessary means for detecting one or more genes, gene fragments or gene products. The present invention also relates to a use of one or more genes, gene fragments or gene products for determination, diagnosis or follow-up of CTCL or CTCL subtype and for detection of the response to CTCL therapy. The present invention also relates to a use of one or more target molecules for CTCL therapy or for the preparation of a medicament for treating CTCL.

摘要翻译： 本发明涉及遗传学和肿瘤学领域，并提供了检测皮肤T细胞淋巴瘤（CTCL）或对CTCL敏感性的方法。 具体地说，本发明涉及一种诊断和追踪CTCL或CTCL亚型的新方法，该方法包括测定一种或多种基因，基因片段或基因产物的表达。 本发明还涉及检测对CTCL治疗的反应的新方法，所述方法包括测定生物样品中一种或多种基因或基因片段或基因产物的表达。 本发明还涉及一种开发或改进CTCL治疗或开发抗CTCL药物的新方法，该方法包括影响一种或几种基因或基因产物的筛选剂。 本发明还涉及一种治疗CTCL患者的新方法，该方法包括影响一种或几种基因或基因产物。 本发明还涉及一种新的测试试剂盒，该试剂盒包含检测一种或多种基因，基因片段或基因产物的必要手段。 本发明还涉及一种或多种基因，基因片段或基因产物用于测定，诊断或追踪CTCL或CTCL亚型以及检测对CTCL治疗的应答​​的用途。 本发明还涉及一种或多种靶分子用于CTCL治疗或制备用于治疗CTCL的药物的用途。

公开(公告)号：US07989172B2

公开(公告)日：2011-08-02

申请号：US11662878

申请日：2005-09-16

申请人： Riikka Lund ,  Riitta Lahesmaa

发明人： Riikka Lund ,  Riitta Lahesmaa

IPC分类号： G01N33/53 ,  G01N33/567

CPC分类号： C12Q1/6881 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or disposition to, an immune-related disorder in a subject.

摘要翻译： 本发明提供利用与免疫介导的疾病如哮喘，过敏和自身免疫疾病相关的新靶基因的方法。 本发明基于已知T辅助细胞来源的CD4 +前体细胞（Thp）的极化的分子水平描述。 特别地，本发明提供鉴定能够调节CD4 +淋巴细胞的极化的化合物的方法。 本发明还涉及用于评估受试者中免疫相关疾病的存在或处置的方法。

公开(公告)号：US07659077B2

公开(公告)日：2010-02-09

申请号：US10549204

申请日：2004-03-17

申请人： Riikka Lund ,  Zhi Chen ,  Riitta Lahesmaa

发明人： Riikka Lund ,  Zhi Chen ,  Riitta Lahesmaa

IPC分类号： G01N33/53 ,  G01N33/567

CPC分类号： G01N33/564 ,  G01N33/5047 ,  G01N33/505

摘要： The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or a predisposition to, an immune-related disorder in a subject.

摘要翻译： 本发明提供利用与免疫介导的疾病如哮喘，过敏和自身免疫疾病相关的新靶基因的方法。 本发明基于已知T辅助细胞来源的CD4 +前体细胞（Thp）的极化的分子水平描述。 特别地，本发明提供鉴定能够调节CD4 +淋巴细胞的极化的化合物的方法。 本发明还涉及用于评估受试者中免疫相关疾病的存在或倾向的方法。

公开(公告)号：US20080168570A1

公开(公告)日：2008-07-10

申请号：US11662878

申请日：2005-09-16

申请人： Riikka Lund ,  Riitta Lahesmaa

发明人： Riikka Lund ,  Riitta Lahesmaa

IPC分类号： A01K67/027 ,  C12Q1/68 ,  C12Q1/02

CPC分类号： C12Q1/6881 ,  C12Q2600/136 ,  C12Q2600/158

摘要： The present invention provides methods utilizing novel target genes related to immune-mediated diseases, such as asthma, allergy and autoimmune diseases. The invention is based on a molecular level description of the polarization of CD4+ precursor cells (Thp) from which T helper cells are known to originate. Particularly, the present invention provides a method of identifying a compound capable of modulating the polarization of CD4+ lymphocytes. The invention is also related to a method for assessing the presence of, or disposition to, an immune-related disorder in a subject.

摘要翻译： 本发明提供利用与免疫介导的疾病如哮喘，过敏和自身免疫疾病相关的新靶基因的方法。 本发明基于已知T辅助细胞来源的CD4 +前体细胞（Thp）的极化的分子水平描述。 特别地，本发明提供鉴定能够调节CD4 +淋巴细胞的极化的化合物的方法。 本发明还涉及用于评估受试者中免疫相关疾病的存在或处置的方法。